查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933899

罕見自體發炎性疾病治療市場（按藥物類別、給藥途徑、適應症、通路和最終用戶分類），全球預測，2026-2032年

Rare Autoinflammatory Diseases Drug Market by Drug Class, Route Of Administration, Indication, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，罕見自體發炎性疾病治療市場規模將達到 37.8 億美元，到 2026 年將成長至 41.3 億美元，複合年成長率為 9.70%，到 2032 年將達到 72.3 億美元。

關鍵市場統計數據
基準年 2025 37.8億美元
預計年份：2026年 41.3億美元
預測年份 2032 72.3億美元
複合年成長率 (%) 9.70%

全面概述罕見自身發炎性疾病，重點關注不斷發展的診斷方法、治療方法創新以及影響臨床和商業性決策的系統性挑戰。

罕見自體發炎性疾病是一組在遺傳和免疫學上各不相同的疾病，其特徵是先天免疫活化失控、陣發性全身性發炎和多重器官功能障礙。近年來，分子診斷技術的進步、治療方法的拓展以及患者權益倡導的活性化，重塑了臨床診療路徑，並吸引了生物製藥公司、支付方和專科藥房的日益關注。儘管取得了這些進展，臨床實務仍然十分複雜。表現型異質性、診斷延遲以及對標靶治療方法的持續未滿足需求，仍是醫療服務面臨的挑戰。

診斷突破、細胞激素標靶治療、監管柔軟性和數位化醫療模式如何重塑罕見自身發炎性疾病的治療路徑和商業策略

過去幾年，罕見自體發炎性疾病的診斷、治療和患者取得方式發生了翻天覆地的變化。基因定序和通路特異性生物標記實現了早期精準診斷，推動精準醫療從概念走向實踐。這些診斷能力的提升加速了標靶治療適用患者的篩選，並為臨床試驗入組和核准後證據的產生建立了明確的衡量標準。同時，治療創新也轉向了細胞激素靶向生物製劑和新型小分子抑制劑，旨在抑制特定的發炎介質，同時減少傳統皮質類固醇的脫靶效應。

評估新興關稅趨勢將如何改變生物製藥供應鏈、分銷經濟、臨床試驗物流以及整個治療價值鏈的准入策略。

2025年生效的新關稅可能會重塑依賴複雜供應鏈和進口組件的治療藥物的生產、分銷和定價策略。生物製藥通常需要專門的生產投入和無菌低溫運輸物流，因此對進口成本的變化特別敏感。如果關稅調整導致到岸成本上升，製造商可能立即面臨重新評估籌資策略、調整受影響市場產品價格或降低利潤以維持病患用藥的壓力。隨著時間的推移，這些壓力可能會加速製造地的策略轉變，包括提高生產在地化程度以及在免稅地區擴大第三方灌裝包裝夥伴關係。

將特定適應症、亞表現型、治療層級、給藥途徑、分銷模式和年齡層與商業化和臨床策略聯繫起來的高精度細分分析

了解不同細分領域的細微差別對於設計有效的罕見自體發炎性疾病臨床和商業策略至關重要。我們的適應症組合包括冷吡啉相關週期性症候群、遺傳性地中海熱、高免疫球蛋白D症候群和腫瘤壞死因子受體相關週期性症候群。在冷吡啉相關症候群中，不同的臨床表現型，例如遺傳性寒冷自體發炎症候群、Muckle-Wells症候群和新生兒起病的多系統發炎性疾病，會產生不同的診斷和治療需求。這些臨床亞型需要不同的研究終點、不同的安全性優先事項和不同的長期監測需求，進而影響研究設計和證據產生途徑。

美洲、歐洲、中東和非洲以及亞太地區的區域性需求和微妙的市場動態影響市場准入、證據要求和生產選擇。

區域趨勢對罕見自體發炎性疾病市場的研發重點、進入途徑和商業性執行有顯著影響。在美洲，監管路徑和支付體系支持重點關注新型生物製藥的快速上市、強大的患者支持網路以及先進的臨床試驗基礎設施，尤其是那些能夠識別和招募具有明確遺傳亞型患者的基礎設施。同時，某些市場的價格敏感性和支付方的嚴格審查促使製造商加強對療效證據和患者支持服務的投入，以維持藥物的普及。在進口相關成本和不斷變化的貿易政策會影響治療總成本的地區，供應鏈的韌性和製造地的接近性是關鍵的考量。

策略性企業行動包括有針對性的生物製藥開發、製劑創新、診斷夥伴關係以及旨在實現差異化和促進獲取途徑的合作。

在該治療領域運作的公司正採取差異化的策略策略，以平衡科學風險、商業可行性和商業性潛力。鑑於IL-1或IL-6訊號路徑在多種自體發炎性疾病中具有強力的機制證據，主要企業優先研發標靶IL-1或IL-6訊號路徑的特異性生物製藥製劑；而其他公司則致力於研發小分子抑制劑或老藥新用藥物，以期獲得給藥途徑或成本優勢。在整個競爭格局中，各公司都在投資製劑研發，以實現皮下和口服給藥，從而拓展處方途徑並減少對輸液中心的依賴。

為確保價值鏈的韌性，開發商和支付方應專注於以下實際策略事項：透過投資製劑和診斷技術擴大患者可及性，並展現永續價值。

產業領導者應採取一系列切實可行的措施，以確保穩健的研發路徑和持續的病患用藥。首先，需要投資供應鏈多元化和替代生產方式，以降低貿易中斷風險，並維護生物製藥的低溫運輸完整性。其次，在臨床適用的情況下，優先開發皮下或口服製劑，這將有助於擴大治療場所，使其不再局限於輸液中心，並提高患者的便利性和依從性。第三，在研發早期階段就納入衛生經濟學規劃，以產生支付方日益重視的高成本療法所需的比較療效和長期療效證據。

調查方法概述：結合混合式一手訪談、系統性二手證據綜合和迭代檢驗，以確保為相關人員提供可靠且可操作的研究結果。

本分析所依據的研究結合了結構化的初步研究（與領域專家的對話）和系統的二手證據綜合，以確保研究結果的可靠三角驗證。初步研究包括對自身發炎症候群臨床醫生、供應鏈和分銷主管、監管事務專家以及患者權益倡導者進行深入訪談，以了解實際運作情況和未滿足的需求。二級資訊來源包括同行評審的臨床文獻、監管核准和指導文件、已發表的臨床試驗通訊協定以及匯總的臨床註冊報告，從而使分析建立在檢驗的臨床和政策進展之上。

整合科學進步、營運需求和區域貿易影響，以確定從治療創新到患者持續獲得治療的可行路徑。

罕見自體發炎性疾病領域既蘊含著巨大的科學機遇，也面臨著營運上的複雜性。標靶治療和診斷技術的進步為改善治療效果開闢了重要途徑，但要充分發揮這些潛力，需要製定綜合策略，以應對生產、分銷、醫保參與和患者識別等方面的挑戰。治療方法類型、給藥途徑和分銷管道之間的相互作用，將決定臨床應用模式以及不同患者群體中治療模式的長期永續性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 罕見自體發炎性疾病藥物市場（依藥物類別分類）

  • 生物製藥
    • IL-1抑制劑
    • IL-6抑制劑
    • TNF抑制劑
  • 皮質類固醇
  • 小分子抑制劑

9. 罕見自體發炎性疾病藥物市場（依給藥途徑分類）

  • 靜脈注射
  • 口服
  • 皮下注射

第10章：罕見自體發炎性疾病藥物市場（依適應症分類）

  • 冷吡啉相關週期性綜合症
    • 遺傳性寒冷自體發炎症候群
    • 麥考爾-韋爾斯症候群
    • 新生兒發病的多系統發炎性疾病
  • 遺傳性地中海熱
  • 高免疫球蛋白D症候群
  • 腫瘤壞死因子受體相關週期性症候群

第11章 罕見自體發炎性疾病藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章：按最終用戶分類的罕見自體發炎性疾病藥物市場

  • 成年患者
  • 老年患者
  • 兒童患者

第13章：各地區罕見自體發炎性疾病藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：罕見自身發炎性疾病藥物市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：各國罕見自體發炎性疾病藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國罕見自體發炎性疾病治療市場

第17章：中國罕見自體發炎性疾病治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AB2 Bio Ltd
  • ACELYRIN, Inc.
  • Aslan Pharmaceuticals Limited
  • BioCryst Pharmaceuticals, Inc.
  • CSL Behring GmbH
  • Humanigen, Inc.
  • Immedica Pharma AB
  • Inmagene Biopharmaceuticals
  • Janssen Biotech, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Mabpharm Limited
  • Novartis AG
  • Pharming Group NV
  • Regeneron Pharmaceuticals, Inc.
  • RPharm
  • Swedish Orphan Biovitrum AB
  • Takeda Pharmaceutical Company Limited
  • Zydus Lifesciences Limited
Product Code: MRR-C36616F699B2

The Rare Autoinflammatory Diseases Drug Market was valued at USD 3.78 billion in 2025 and is projected to grow to USD 4.13 billion in 2026, with a CAGR of 9.70%, reaching USD 7.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.78 billion
Estimated Year [2026] USD 4.13 billion
Forecast Year [2032] USD 7.23 billion
CAGR (%) 9.70%

A comprehensive orientation to rare autoinflammatory disorders highlighting diagnostic evolution, therapeutic innovation, and systemic challenges influencing clinical and commercial decisions

Rare autoinflammatory diseases represent a group of genetically and immunologically distinct conditions characterized by dysregulated innate immune activation, episodic systemic inflammation, and multi-organ involvement. Over recent years, advancements in molecular diagnostics, an expanding therapeutic armamentarium, and a growing patient advocacy movement have reshaped clinical pathways and heightened interest across biopharma, payers, and specialty pharmacies. Despite these advances, the clinical landscape remains complex: heterogeneous phenotypes, delayed diagnosis, and an unmet need for durable, targeted therapies continue to challenge care delivery.

Clinicians increasingly rely on genetic testing and biomarker-guided approaches to differentiate entities such as cryopyrin-associated periodic syndromes, familial Mediterranean fever, and other monogenic autoinflammatory disorders from autoimmune and infectious causes. At the same time, therapeutic modalities have evolved from broad immunosuppression toward precision biologics that target specific cytokine pathways. This transition has introduced new considerations around route of administration, long-term safety, and real-world adherence, especially across adult, geriatric, and pediatric populations.

Consequently, stakeholders must navigate a multi-dimensional ecosystem that includes evolving regulatory expectations, novel distribution channels, and shifting payer dynamics. The combination of scientific progress and operational complexity now demands integrated strategies that bridge clinical development, health economics, and patient-centric access solutions. In the sections that follow, we examine the transformative inflection points, regulatory and trade headwinds, and segmentation- and region-specific insights that should guide planning for the next phase of innovation and commercialization.

How diagnostic breakthroughs, cytokine-targeted therapies, regulatory agility, and digital care models are reshaping treatment pathways and commercial strategy in rare autoinflammatory disease

The last several years have ushered in transformative shifts that have redefined how rare autoinflammatory diseases are diagnosed, treated, and delivered to patients. Precision medicine has moved from concept to practice as genetic sequencing and pathway-focused biomarkers enable earlier and more accurate diagnoses. These diagnostic capabilities have accelerated patient identification for targeted therapies, creating clearer signals for clinical trial enrollment and post-approval evidence generation. Simultaneously, therapeutic innovation has pivoted toward cytokine-targeted biologics and novel small molecule inhibitors that aim to suppress specific inflammatory mediators with fewer off-target effects than traditional corticosteroids.

Concurrently, regulatory frameworks have adapted to the realities of rare disease development, with expedited review pathways and increased willingness to accept surrogate endpoints under certain conditions. This regulatory agility has encouraged developers to explore adaptive trial designs and hybrid real-world/clinical evidence strategies to demonstrate meaningful benefit in small, heterogenous populations. Digital health and telemedicine have further transformed care pathways, increasing access to specialist clinicians and enabling remote monitoring of disease activity, which enhances both clinical management and post-marketing surveillance.

Finally, commercial models are evolving as distribution channels diversify and payers emphasize value-based arrangements. Manufacturers are responding by investing in patient support programs, alternative dosing formulations, and real-world evidence platforms to demonstrate long-term benefit and cost-effectiveness. Taken together, these shifts create a landscape in which scientific innovation and pragmatic commercialization strategies must be tightly integrated to convert clinical promise into sustained patient access.

Assessing how new tariff dynamics can alter biologics supply chains, distribution economics, clinical trial logistics, and access strategies across the therapeutic value chain

The introduction of new tariff measures in 2025 has the potential to reshape manufacturing, distribution, and pricing strategies for therapies that rely on complex supply chains and imported components. Biologics, which often require specialized manufacturing inputs and sterile cold-chain logistics, are particularly sensitive to changes in import costs. When tariff adjustments increase landed costs, manufacturers may face immediate pressure to reassess sourcing strategies, reprice products in affected markets, or absorb margins to preserve patient access. Over time, such pressures can accelerate strategic shifts in manufacturing footprint, including increased regionalization of production or expanded third-party fill/finish partnerships in tariff-exempt jurisdictions.

Distribution channels will also absorb the cumulative impact of tariffs. Hospital pharmacies that procure high-cost biologics for inpatient or infusion-based care may face procurement constraints, prompting greater reliance on outpatient administration or subcutaneous alternatives that reduce hospital resource utilization. Online and retail pharmacies, which can facilitate home-delivery models and patient support services, may see growth as stakeholders seek to mitigate distribution friction. Payers and health systems will intensify scrutiny of channel economics and may negotiate different contracting terms or demand outcomes-based arrangements to offset the financial uncertainty introduced by tariff changes.

Clinical development and global trial planning are not immune. Sponsors may reconsider trial site selection to reduce exposure to tariff-affected logistics for investigational product shipments and ancillary supplies. Regulatory interactions could become more complex as authorities weigh the downstream effects of tariffs on drug availability and continuity of care. In sum, the tariff environment underscores the importance of supply chain resilience, multi-jurisdictional manufacturing strategies, and flexible commercial models that can preserve both innovation and patient access under shifting trade conditions.

Deeply granular segmentation insights linking specific indications, sub-phenotypes, therapeutic classes, routes, distribution patterns, and age cohorts to commercialization and clinical strategies

Segment-level nuance is central to designing effective clinical and commercial strategies for rare autoinflammatory diseases. The portfolio of indications includes cryopyrin-associated periodic syndromes, familial Mediterranean fever, hyperimmunoglobulin D syndrome, and tumor necrosis factor receptor associated periodic syndrome; within cryopyrin-associated syndromes, distinct clinical phenotypes such as familial cold autoinflammatory syndrome, Muckle-Wells syndrome, and neonatal-onset multisystem inflammatory disease create divergent diagnostic and therapeutic needs. These clinical subtypes drive heterogeneous trial endpoints, differing safety priorities, and distinct long-term monitoring requirements, which in turn influence trial design and evidence-generation pathways.

Therapeutic modality remains a primary determinant of development and commercialization approaches. Biologics, which encompass IL-1 inhibitors, IL-6 inhibitors, and TNF inhibitors, carry unique manufacturing and distribution demands as well as differentiated clinical profiles compared with corticosteroids and small molecule inhibitors. Biologics often warrant investment in cold-chain logistics and specialized patient support while small molecule options may offer advantages in oral administration, formulary placement, and broader prescriber uptake. Route of administration further refines these decisions: intravenous therapies often require infusion center capacity and can impose higher direct care costs, oral agents support outpatient management and ease adherence for chronic regimens, and subcutaneous formulations provide a middle ground that facilitates home administration and can improve patient convenience and retention.

Distribution channel choice directly affects patient access and the economics of care. Hospital pharmacies play a central role in administering infusion-based treatments and managing acutely ill patients, while online pharmacies and retail pharmacy networks expand reach for home-delivered biologics or oral agents and support ongoing adherence. End-user segmentation by age-adult, geriatric, and pediatric patients-introduces additional complexity because dosing strategies, safety monitoring, and formulation preferences differ across life stages. Pediatric populations, for example, require careful consideration of growth and developmental impacts and often depend on specialized centers, whereas geriatric patients bring comorbidity and polypharmacy considerations that can influence safety profiles and payer coverage decisions. Integrating these segmentation layers is essential for prioritizing development assets, optimizing route and formulation strategies, tailoring patient support, and aligning reimbursement discussions with the heterogeneous needs of clinicians and patients.

Regional imperatives and nuanced market dynamics across the Americas, Europe-Middle East-Africa, and Asia-Pacific that shape access, evidence demands, and manufacturing choices

Regional dynamics materially influence development priorities, access pathways, and commercial execution across rare autoinflammatory disease markets. In the Americas, regulatory pathways and payer systems support a strong emphasis on rapid adoption of novel biologics, robust patient advocacy networks, and advanced clinical trial infrastructure, particularly for networks that can identify and enroll patients with well-characterized genetic subtypes. Meanwhile, price sensitivity and payer scrutiny in certain markets drive manufacturers to invest in outcomes evidence and patient support services to sustain uptake. Supply-chain resilience and manufacturing proximity become key considerations where import-related costs or trade policy shifts alter total cost of therapy.

Europe, the Middle East & Africa brings a diverse spectrum of regulatory frameworks and reimbursement environments. Centralized review mechanisms in some European jurisdictions coexist with multi-country health technology assessment processes that prioritize comparative effectiveness data. This region often requires tailored health economic dossiers and real-world evidence to secure favorable access and reimbursement. Fragmentation across countries necessitates bespoke pricing and distribution strategies, and partnerships with specialty pharmacies and academic referral centers remain critical to reach rare disease patients.

In Asia-Pacific, rapid growth in clinical research capacity, increasing domestic biomanufacturing capabilities, and evolving payer systems create both opportunities and challenges. Some markets are accelerating local regulatory reforms to attract rare disease investment, while others remain constrained by limited diagnostics infrastructure and variable reimbursement policies. Strategic engagement with regional clinical networks, investment in diagnostic capacity building, and considerations around local production or licensing can be decisive in ensuring supply continuity and market entry. Across all regions, harmonizing evidence generation, aligning with local diagnostic practices, and adapting distribution strategies to the realities of each healthcare system are essential to translate scientific advances into sustainable patient access.

Strategic company behaviors including targeted biologic development, formulation innovation, diagnostic partnerships, and operational alliances that drive differentiation and access

Companies operating in this therapeutic space are adopting differentiated strategic postures to balance scientific risk, operational feasibility, and commercial potential. Leading developers prioritize pathway-specific biologics that target IL-1 or IL-6 signaling given the strong mechanistic rationale in many autoinflammatory disorders, while others pursue small molecule inhibitors or repurposed agents that may offer advantages in route of administration and cost of goods. Across the competitive landscape, organizations are investing in formulation science to enable subcutaneous or oral delivery, thereby broadening potential prescribing settings and reducing dependence on infusion centers.

Beyond product design, commercial success increasingly depends on integrated patient support ecosystems. Firms that build robust diagnostic alliances, deploy focused patient identification programs, and offer comprehensive adherence and reimbursement support gain earlier traction with prescribers and payers. Strategic partnerships-whether with contract manufacturing organizations to expand fill/finish capacity, with specialty pharmacies to enhance home-delivery models, or with diagnostic companies to co-develop companion tests-are common approaches to de-risk commercialization.

At the portfolio level, companies are hedging regulatory and pricing uncertainty through diversified pipelines and by pursuing adaptive clinical strategies that blend randomized data with real-world evidence. Mergers and alliances are being evaluated not only for pipeline synergies but also for operational capabilities in manufacturing and global distribution. Ultimately, firms that can align scientific differentiation with pragmatic access strategies will be best positioned to convert regulatory approvals into lasting patient benefit and sustainable revenue streams.

Practical strategic priorities for developers and payers to secure resilient supply chains, broaden patient access through formulation and diagnostic investments, and demonstrate sustainable value

Industry leaders should adopt a series of actionable measures to ensure resilient development pathways and durable patient access. First, invest in supply-chain diversification and contingency manufacturing to mitigate exposure to trade disruptions and to sustain cold-chain integrity for biologic therapies. Second, prioritize development of subcutaneous or oral formulations where clinically appropriate to expand treatment settings beyond infusion centers and to improve patient convenience and adherence. Third, embed health economic planning early in development to generate the comparative effectiveness and long-term outcomes evidence that payers increasingly require for high-cost therapies.

Additionally, strengthen collaborations with diagnostic providers and specialist referral networks to accelerate accurate diagnosis and streamline patient identification for trials and treatment. Invest in robust real-world evidence platforms that capture longitudinal clinical outcomes, safety signals, and health resource utilization, enabling more compelling value propositions for payers and health systems. Expand patient support services including education, adherence programs, and financial navigation to lower barriers to initiation and continuation of therapy. Embrace innovative contracting models with payers, such as outcomes-based agreements, to share risk and demonstrate value over time.

Finally, prioritize regulatory engagement across jurisdictions to align on acceptable endpoints, surrogate markers, and post-approval evidence commitments. These combined actions will enable a flexible, patient-centered commercial approach that preserves innovation incentives while addressing payer and provider concerns about affordability and long-term impact.

A methodological overview describing blended primary interviews, systematic secondary evidence synthesis, and iterative triangulation to ensure reliable, actionable insights for stakeholders

The research underpinning this analysis combined structured primary engagement with domain experts and systematic secondary evidence synthesis to ensure robust, triangulated insights. Primary inputs included in-depth interviews with clinicians specializing in autoinflammatory syndromes, supply-chain and distribution executives, regulatory affairs professionals, and patient advocacy leaders to capture operational realities and unmet needs. Secondary sources encompassed peer-reviewed clinical literature, regulatory approvals and guidance documents, published clinical trial protocols, and aggregated clinical registry reports to ground the narrative in verifiable clinical and policy developments.

Data synthesis emphasized cross-validation to reconcile differing perspectives and to identify consistent themes that persist across geographies and stakeholder groups. Methodological rigor was applied through iterative hypothesis testing, scenario analysis for trade and distribution impacts, and qualitative coding of interview transcripts to surface recurring operational barriers and opportunity areas. The research process maintained transparency about limitations inherent to rare disease work, including small patient cohorts and heterogeneity of clinical presentations, and recommendations explicitly account for these constraints by favoring adaptable and evidence-building strategies.

Ethical considerations guided engagement with clinicians and advocates, and confidentiality protections were applied where requested. The methodology prioritized practical relevance for decision-makers by focusing on actionable insight rather than speculative projections, and the full report provides appendix-level detail on interview protocols, source lists, and analytic assumptions for those seeking deeper methodological transparency.

Synthesis of scientific progress, operational imperatives, and regional trade effects defining the actionable pathway from therapeutic innovation to sustained patient access

Rare autoinflammatory diseases present a convergence of scientific opportunity and operational complexity. Advances in targeted therapies and diagnostics have created a meaningful pathway to improved outcomes, yet the realization of that potential depends on integrated strategies that address manufacturing, distribution, payer engagement, and patient identification. The interplay between therapeutic modality, route of administration, and distribution channel will determine both clinical adoption patterns and the long-term sustainability of care models across diverse patient cohorts.

Regional policy environments and trade dynamics add layers of strategic consideration, as do the distinct needs of adult, geriatric, and pediatric populations. Companies that proactively align clinical development with pragmatic access strategies-investing in formulation innovation, diagnostic partnerships, and real-world evidence-will be better positioned to navigate reimbursement scrutiny and to secure durable uptake. Decision-makers should treat supply-chain resilience, early payer engagement, and patient-centric design as core pillars of program planning rather than afterthoughts.

In conclusion, the pathway from molecular insight to patient benefit is narrowing, but success will require orchestration across scientific, operational, and commercial dimensions. Executives who integrate these elements and act with deliberate agility will convert therapeutic potential into meaningful, sustained improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Rare Autoinflammatory Diseases Drug Market, by Drug Class

  • 8.1. Biologics
    • 8.1.1. Il-1 Inhibitors
    • 8.1.2. Il-6 Inhibitors
    • 8.1.3. Tnf Inhibitors
  • 8.2. Corticosteroids
  • 8.3. Small Molecule Inhibitors

9. Rare Autoinflammatory Diseases Drug Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Rare Autoinflammatory Diseases Drug Market, by Indication

  • 10.1. Cryopyrin-Associated Periodic Syndromes
    • 10.1.1. Familial Cold Autoinflammatory Syndrome
    • 10.1.2. Muckle-Wells Syndrome
    • 10.1.3. Neonatal-Onset Multisystem Inflammatory Disease
  • 10.2. Familial Mediterranean Fever
  • 10.3. Hyperimmunoglobulin D Syndrome
  • 10.4. Tumor Necrosis Factor Receptor Associated Periodic Syndrome

11. Rare Autoinflammatory Diseases Drug Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Rare Autoinflammatory Diseases Drug Market, by End User

  • 12.1. Adult Patients
  • 12.2. Geriatric Patients
  • 12.3. Pediatric Patients

13. Rare Autoinflammatory Diseases Drug Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Rare Autoinflammatory Diseases Drug Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Rare Autoinflammatory Diseases Drug Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Rare Autoinflammatory Diseases Drug Market

17. China Rare Autoinflammatory Diseases Drug Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AB2 Bio Ltd
  • 18.6. ACELYRIN, Inc.
  • 18.7. Aslan Pharmaceuticals Limited
  • 18.8. BioCryst Pharmaceuticals, Inc.
  • 18.9. CSL Behring GmbH
  • 18.10. Humanigen, Inc.
  • 18.11. Immedica Pharma AB
  • 18.12. Inmagene Biopharmaceuticals
  • 18.13. Janssen Biotech, Inc.
  • 18.14. Kiniksa Pharmaceuticals, Ltd.
  • 18.15. Mabpharm Limited
  • 18.16. Novartis AG
  • 18.17. Pharming Group N.V.
  • 18.18. Regeneron Pharmaceuticals, Inc.
  • 18.19. RPharm
  • 18.20. Swedish Orphan Biovitrum AB
  • 18.21. Takeda Pharmaceutical Company Limited
  • 18.22. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-1 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY IL-6 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TNF INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL COLD AUTOINFLAMMATORY SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY MUCKLE-WELLS SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY NEONATAL-ONSET MULTISYSTEM INFLAMMATORY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY FAMILIAL MEDITERRANEAN FEVER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HYPERIMMUNOGLOBULIN D SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ADULT PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GERIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY PEDIATRIC PATIENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 151. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 152. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 153. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 154. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 155. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. GCC RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 175. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 176. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 177. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 178. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 179. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. G7 RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 182. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 183. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 184. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 186. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 187. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY BIOLOGICS, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA RARE AUTOINFLAMMATORY DISEASES DRUG MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)